Daptomycin + Vancomycin
Phase 3Completed 0 watching 0 views this week📈 Rising
77
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Skin Diseases
Conditions
Skin Diseases, Infectious
Trial Timeline
Sep 1, 2008 → Sep 1, 2010
NCT ID
NCT00772447About Daptomycin + Vancomycin
Daptomycin + Vancomycin is a phase 3 stage product being developed by AstraZeneca for Skin Diseases. The current trial status is completed. This product is registered under clinical trial identifier NCT00772447. Target conditions include Skin Diseases, Infectious.
Hype Score Breakdown
Clinical
27
Activity
18
Company
10
Novelty
9
Community
10
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00772447 | Phase 3 | Completed |
Competing Products
20 competing products in Skin Diseases